Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 2019 | Published
Journal Article Open

Concise Review: Lessons Learned from Islet Transplant Clinical Trials in Developing Stem Cell Therapies for Type 1 Diabetes

Abstract

We examined data and patterns in clinical islet transplant studies registered on clinicaltrials.gov (CTgov) for treatment of type 1 diabetes (T1D), with a goal of extracting insights to apply in the design of a pluripotent stem cell‐derived islet therapy. Clinical islet transplantation, as a cell therapy (rather than solid organ transplant) is a unique precedent for stem cell‐based islet therapies. Registration activity shows that the field is not growing significantly, and newer registrations suggest that the reasons for stagnation include need for a more optimal site of infusion/transplantation, and especially a need for better immune protective strategies to advance a more effective and durable therapy for T1D.

Additional Information

© 2018 The Authors. Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. Received July 17, 2018; revised September 14, 2018; accepted for publication October 3, 2018. Author Contributions: C.A.W.: conception and design, data collection, analysis and interpretation, manuscript writing; W.L.R.: data analysis and interpretation, manuscript writing; M.C.: conception and design, data collection, analysis and interpretation, manuscript writing; C.A.W., W.L.R., and M.C.: final approval of manuscript. Disclosure of Potential Conflicts of Interest: C.A.W. discloses employment with R&D stage company. W.L.R. discloses employment and inventor/patent holder with R&D stage company. M.C. discloses Consultant/Advisory role with Seraxis, Inc.

Attached Files

Published - Welsch_et_al-2019-STEM_CELLS_Translational_Medicine.pdf

Files

Welsch_et_al-2019-STEM_CELLS_Translational_Medicine.pdf
Files (2.3 MB)

Additional details

Created:
August 19, 2023
Modified:
October 19, 2023